Madhu Menon, MD, PhD, FCAP, ARUP’s section chief of Hematopathology, works with a team of experts to deliver accurate and timely results.
The field of hematopathology has rapidly evolved from pure microscopy and immunophenotype-based classifications to incorporate cytogenetics, molecular data, and next generation sequencing (NGS) data in an integrated approach to diagnosis. ARUP Laboratories evaluates the data in a unique, consensus-driven way to quickly deliver accurate results for clinicians and patients.
The entire Hematopathology department meets weekly to discuss difficult cases, and subject matter experts are always available for second opinions on urgent cases. They look at morphology, flow cytometry, and the mutational profile. Then the group of dedicated hematopathologists, laboratory analysts, clinical variant scientists, and medical directors pulls all the data points together and works toward a diagnosis.
ARUP’s new myeloid malignancies mutation and copy number variation assay uses NGS to detect sequence variants, copy number variants (CNVs), and copy number-neutral loss of heterozygosity (CN-LOH). In addition to targeting specific genes, this panel test detects and reports relevant CNVs down to 5 Mb from across the genome. The test covers all the latest variants relevant for diagnosis and classification of myeloid malignancies, as well as emerging biomarkers that may inform clinical management.
Madhu Menon, MD, PhD, FCAP, ARUP’s section chief of Hematopathology, says the consensus approach, access to subject-matter experts, complex in-house ancillary testing, and the latest technologies set ARUP apart.
“You can draw [on] the expertise of various people in the group, and we are a large group of board-certified hematopathologists, all with different areas of expertise and interests,” Menon said. “The back-and-forth within the group leaves less chance for error.”
Menon recently helped launch a webinar series to share advances in the hematopathology field. The first webinar featured Tracy George, MD, chief scientific officer and president of the Innovation Business Unit at ARUP, for a discussion of the past, present, and future of hematopathology. Both experts will participate in the American Society of Hematology (ASH) Annual Meeting and Exposition on December 9–12 in San Diego, California.
ARUP medical directors and scientists are involved in several abstracts and poster sessions at the meeting, and Margaret Williams, MD, medical director of Hematopathology, will present a workshop entitled, “Somatic Pathogenic UBA1 Mutations Predispose Male Patients to Myeloid Neoplasms,” on Friday, December 8, at 4:18 p.m.
ARUP experts and consultants will be available at booth #2453 throughout the conference.
Learn more about ARUP’s involvement at ASH here.
Read about ARUP experts’ abstracts and poster sessions here.
The next episode of the Hematopathology Expert Series is scheduled for Spring 2024. Watch the Fall 2023 session, “State of Hematopathology: The Past, Present, and the Future,” here.
Bonnie Stray, firstname.lastname@example.org